XML 54 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended
Nov. 30, 2014
Nov. 30, 2013
Cash flows from operating activities    
Net income $ 528,904us-gaap_NetIncomeLoss $ 685,155us-gaap_NetIncomeLoss
Adjustments to reconcile net income to net cash provided by operating activities    
Depreciation and amortization of property and equipment 93,036us-gaap_DepreciationDepletionAndAmortization 11,903us-gaap_DepreciationDepletionAndAmortization
Amortization of capitalized computer software development costs 213,290us-gaap_CapitalizedComputerSoftwareAmortization 191,829us-gaap_CapitalizedComputerSoftwareAmortization
Amortization of Intellectual property 151,875us-gaap_AmortizationOfIntangibleAssets 1,875us-gaap_AmortizationOfIntangibleAssets
Stock-based compensation 65,799us-gaap_ShareBasedCompensation 15,360us-gaap_ShareBasedCompensation
Deferred income taxes 32,370us-gaap_DeferredIncomeTaxExpenseBenefit 70,178us-gaap_DeferredIncomeTaxExpenseBenefit
(Increase) decrease in    
Accounts receivable (353,283)us-gaap_IncreaseDecreaseInAccountsReceivable (40,957)us-gaap_IncreaseDecreaseInAccountsReceivable
Revenues in excess of billings (177,880)us-gaap_IncreaseDecreaseInCostInExcessOfBillingOnUncompletedContract 0us-gaap_IncreaseDecreaseInCostInExcessOfBillingOnUncompletedContract
Prepaid income taxes 122,231us-gaap_IncreaseDecreaseInPrepaidExpense 236,775us-gaap_IncreaseDecreaseInPrepaidExpense
Prepaid expenses and other assets 12,788us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 19,098us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable (36,753)us-gaap_IncreaseDecreaseInAccountsPayable 89,408us-gaap_IncreaseDecreaseInAccountsPayable
Accrued payroll and other expenses (112,413)us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities 26,394us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities
Accrued bonus (96,000)us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities (30,000)us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities
Billings in excess of revenues (216,715)us-gaap_IncreaseDecreaseInBillingInExcessOfCostOfEarnings 0us-gaap_IncreaseDecreaseInBillingInExcessOfCostOfEarnings
Other liabilities (4,965)us-gaap_IncreaseDecreaseInOtherCurrentLiabilities (4,965)us-gaap_IncreaseDecreaseInOtherCurrentLiabilities
Deferred revenue 4,509us-gaap_IncreaseDecreaseInDeferredRevenue 79,014us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash provided by operating activities 226,793us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 1,351,067us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities    
Purchases of property and equipment (20,944)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (9,843)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Cash used to purchase Cognigen (2,080,000)us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates 0us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates
Cash received in acquisition 190,184us-gaap_CashAcquiredFromAcquisition 0us-gaap_CashAcquiredFromAcquisition
Capitalized computer software development costs (297,729)us-gaap_PaymentsToDevelopSoftware (373,204)us-gaap_PaymentsToDevelopSoftware
Net cash provided by (used in) investing activities (2,208,489)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (383,047)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities    
Payment of Dividends (842,056)us-gaap_PaymentsOfDividends (642,956)us-gaap_PaymentsOfDividends
Proceeds from the exercise of stock options 0us-gaap_ProceedsFromStockOptionsExercised 50,345us-gaap_ProceedsFromStockOptionsExercised
Net cash (used in) financing activities of continuing operations (842,056)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations (592,611)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase (decrease) in cash and cash equivalents (2,823,752)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 375,409us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of year 8,614,929us-gaap_CashAndCashEquivalentsAtCarryingValue 10,179,298us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 5,791,177us-gaap_CashAndCashEquivalentsAtCarryingValue 10,554,707us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosures of cash flow information    
Interest paid 0us-gaap_InterestPaid 0us-gaap_InterestPaid
Income taxes paid 3,232us-gaap_IncomeTaxesPaid 0us-gaap_IncomeTaxesPaid
Non-Cash Investing and Financing    
Stock issued for acquisition of Cognigen Corporation 3,277,171us-gaap_StockIssuedDuringPeriodValueAcquisitions 0us-gaap_StockIssuedDuringPeriodValueAcquisitions
Creation of contract liability for acquisition of Cognigen Corporation $ 1,854,405simu_CreationOfContractLiabilityForAcquisitionOfCognigenCorporation $ 0simu_CreationOfContractLiabilityForAcquisitionOfCognigenCorporation